As such, sequential targeting of the MAPK pathway at multiple nodes in BRAF mutant patients (irrespective of their RAS mutational status) or targeting of parallel pathways, such as PI3K, in RAS mutant patients, may also improve the therapeutic response of melanoma patients to MEK1/2 inhibition[20,22,23]. This evidence concerns the gene MAP2K1 and melanoma.